Patricia Hartge

Patricia Hartge is a renowned epidemiologist and biostatistician known for her significant contributions to the field of cancer epidemiology. She has been instrumental in the development and execution of large-scale cohort studies and case-control studies that have provided valuable insights into the environmental and genetic risk factors of various types of cancer.

Early Life and Education[edit | edit source]

Patricia Hartge was born and raised in the United States. She pursued her undergraduate studies in mathematics and later earned her ScD in Biostatistics and Epidemiology from the Harvard School of Public Health. Her academic pursuits laid a strong foundation for her future career in cancer epidemiology.

Career[edit | edit source]

Hartge began her career at the National Cancer Institute (NCI), where she worked on several large-scale epidemiological studies. Her work primarily focused on understanding the environmental and genetic risk factors associated with various types of cancer, including ovarian cancer, pancreatic cancer, and lymphoma.

One of her most notable contributions is her work on the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, a large-scale, randomized trial designed to determine the effects of screening on cancer-related mortality and secondary endpoints in men and women aged 55 to 74.

Contributions to Cancer Epidemiology[edit | edit source]

Hartge's research has significantly advanced our understanding of cancer risk factors. Her work has helped identify several environmental and genetic factors associated with increased cancer risk. She has also contributed to the development of methodologies for epidemiological studies, improving the accuracy and reliability of these studies.

Awards and Recognition[edit | edit source]

In recognition of her contributions to the field of cancer epidemiology, Hartge has received several awards and honors. These include the American Association for Cancer Research's Award for Outstanding Achievement in Cancer Research and the American Society of Clinical Oncology's Special Recognition Award.